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Andersen-Tawil syndrome (ATS) is a rare autosomal domi-
nant or sporadic disorder deﬁned by a triad of periodic muscle
paralysis, ventricular arrhythmias (long QT-7), and dysmor-
phic features. The estimated prevalence is 1 in 1,000,000.1,2
The underlying mutation is in the KCNJ2 gene encoding the
inward rectiﬁer potassium channels (Kir2.1) present in both
skeletal and cardiac muscles. About 80%90% of ATS cases
have an identiﬁed KCNJ2 mutation, and these cases are
classiﬁed as ATS1, with the rest designated ATS2.1 The
clinical phenotype of the cardiac presentation is varied, ranging
from prolonged QT interval, prominent Uwave, and premature
ventricular complexes (PVCs) to bidirectional ventricular
tachycardia and, rarely, ventricular ﬁbrillation or sudden
cardiac death (SCD). Ventricular arrhythmias are precipitated
by adrenergic stimuli like exercise or intense emotion, which
accounts for the use of beta-blockers as standard therapy.3 We
present a case of ATS with ventricular arrhythmias not
responsive to different antiarrhythmics including beta-
blockers and managed successfully with atrial pacing.
Case report
A 58-year-old white woman with a lifelong history of
hyperkalemic periodic muscle paralysis and bidirectional
ventricular tachycardia diagnosed 50 years prior presented to
the clinic for follow-up of symptomatic PVCs. She had no
known history of coronary artery disease. She had been
treated with sequential monotherapy of multiple antiarrhyth-
mic agents, including quinidine, mexiletene, dronedarone,
and propanolol, without signiﬁcant suppression of PVCs.KEYWORDS Andersen-Tawil syndrome; Atrial pacing; Electrophysiology;
Implantable cardioverter-deﬁbrillator; Long QT syndrome; Ventricular
arrhythmia
ABBREVIATIONS ATS ¼ Andersen-Tawil syndrome; ECG ¼ electro-
cardiogram; PVC ¼ premature ventricular complex; QTc ¼ corrected
QT interval; SCD ¼ sudden cardiac death
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implanted for recurrent syncope with prolonged corrected
QT (QTc) interval noted on electrocardiogram (ECG) and
nonsustained runs of ventricular tachycardia noted on
ambulatory monitoring. She was on acetazolamide for
control of periodic paralysis. There was no family history
of SCD or periodic muscle paralysis. Physical examination
was signiﬁcant for a regularly irregular cardiac rhythm and
the presence of dysmorphic features—microcephaly, facial
asymmetry, thin helices, pinched nose, small alae nase, thin
upper lip, small ﬁngers, ﬁfth ﬁnger clinodactyly bilaterally,
small feet, and 2-3 toe syndactyly bilaterally. ECG showed
frequent PVCs in a bigeminy pattern and a QTc of 535 ms, as
shown in Figure 1. A PVC burden of 35,000 per day was
noted on Holter monitoring. Electrophysiology testing
showed that the focus of the PVCs was at the base of the
papillary muscles. The patient underwent 2 PVC ablations
but had recurrence of different PVC morphologies. She
continued to remain symptomatic.
Owing to the presence of the typical triad, there was a
suspicion of ATS. Subsequent genetic testing conﬁrmed she
was a heterozygote for the KCNJ2 gene mutation C.407C4T,
P.S136F. Ventricular arrhythmias had not been responsive to
multiple antiarrhythmic agents or PVC ablation. On electro-
physiology testing, vagal stimuli slowed the sinus rate and
allowed the abnormal rhythm to take over while atropine
promoted normal sinus rhythm. A recent case report from Japan
indicated that atrial pacing was successful in reducing PVC
burden after ﬁndings of increased PVC frequency after meals or
during sleep, suggesting PVCs were vagal-dependent.4 There-
fore, an atrial lead was implanted in our patient to provide
continuous overdrive pacing at 80 beats per minute. There was
a reduction in the PVC burden in the postoperative period. One
year later, she continues to have a low PVC burden (24 per
day), normalized QTc of 385 ms, absent PVCs on ECG
(Figure 2), and improvement in quality of life.Discussion
There are no randomized clinical trials that have evaluated
the efﬁcacy of current management strategies for ventricularpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.06.011
KEY TEACHING POINTS
 Andersen-Tawil syndrome is a differential diagnosis
of bidirectional ventricular tachycardia. In the
clinical setting of ventricular arrhythmias since
childhood, periodic muscle paralysis, and
dysmorphic features, the diagnosis of Andersen-
Tawil syndrome should be considered.
 The ﬁrst-line therapy of ventricular arrhythmias due
to Andersen-Tawil syndrome is beta-blockers, along
with avoidance of QT-prolonging medications.
 Atrial pacing at a higher rate than the intrinsic
pacemaker stimulus is a consideration for
management of ventricular arrhythmias resistant
to ﬁrst-line therapy.
353Fadahunsi et al Atrial Pacing in Andersen-Tawil Syndromearrhythmias in ATS owing to extremely low incidence.
Fortunately, compared to other long QT syndromes or
catecholaminergic polymorphic ventricular tachycardia, the
occurrence of malignant tachyarrhythmias is relatively
uncommon in ATS.1 Although most patients are asympto-
matic from the PVCs, those who are symptomatic experience
a reduction in quality of life, like our patient. There is also the
risk of tachycardia-induced cardiomyopathy, hence the need
to control ventricular arrhythmias.5
One of the key management principles is to avoid QT-
prolonging medications that can precipitate torsades. Intense
adrenergic stimuli can sometimes precipitate an episode of
arrhythmia, which accounts for the use of beta-blockersFigure 1 Resting 12-lead electrocardiogram at age 59 years (prior to atrial pa
prolonged QTc of 535 ms.(usually propanolol) as ﬁrst-line treatment based on con-
sensus.3 Beta-blockers are not always successful in reducing
ventricular arrhythmias. There are reports of cases where
arrhythmias are insensitive to catecholamines and were
suppressed during periods of intense activity, such as
exercise.6 Other medications including calcium-channel
blockers, ﬂecainide, and amiodarone have been used in a
few cases, with varying success rates.3,7,9 A unique combi-
nation of ﬂecainide and verapamil was found to be successful
in a single case study by Janson et al.10 SCD is rare but has
been reported.4,11 For this reason, the implantation of an
implantable cardioverter-deﬁbrillator may be considered for
prevention of SCD in patients at high risk.1,11 However,
there are no guidelines available for identifying these high-
risk cases. The index case presented had failed 2 episodes of
PVC ablation. Similarly, a retrospective French study did not
ﬁnd any beneﬁt for ablation in patients with conﬁrmed
KCNJ2 mutation.12
Overdrive pacing in long QT syndromes (not ATS
speciﬁcally) has been around for many years but is not well
deﬁned.13 There is no clear indication whether it should be
considered for all symptomatic long QT syndrome patients
or restricted to only those who have failed beta-blocker
therapy. Similarly, the effectiveness of overdrive pacing in
all genotypes of long QT syndrome is unknown, as available
studies did not look at pacing effectiveness by genotype.14
Viskin et al15 in 2000 carried out an extensive review on
cardiac pacing in this patient population and suggested that
genotypes 2 and 3 were more likely to beneﬁt from pacing,
but cautioned that the absence of evidence of the efﬁcacy of
pacing in other genotypes should not be taken as evidence ofcing) showing premature ventricular complexes in a bigeminy pattern with
Figure 2 Resting 12-lead electrocardiogram a year post-pacing showing normalization of corrected QT interval (385 ms) and absence of premature ventricular
complexes.
Heart Rhythm Case Reports, Vol 1, No 5, September 2015354nonbeneﬁt. The optimum pacing rate in long QT syndrome is
unknown, although 80 beats per minutes is usually selected
based on observational studies.13 However, this does not
preclude the use of faster rates in patients who continue to
have arrhythmias at a paced rate of 80 beats per minute.
This is the second case report, to our knowledge, that
shows that atrial overdrive pacing may control ventricular
arrhythmias in ATS. This was ﬁrst reported by Kuramoto
et al4 in 2012, when they found their patient had an increased
frequency of PVCs and ventricular tachycardia during
periods of increased vagal stimuli. Her paced rate was
increased to 70 beats per minute, which subsequently
decreased the frequency of PVCs and ventricular arrhyth-
mias. In our patient, following the placement of an atrial lead
and pacing at 80 beats per minute, her PVC burden decreased
and there was subsequent improvement in symptoms and
quality of life. Symptom improvement has persisted for
greater than 15 months.Conclusion
This report identiﬁes the second case of ATS with con-
ﬁrmed KCNJ2 mutation whose ventricular arrhythmias
were successfully managed with atrial pacing. We propose
that further studies are necessary to conﬁrm ﬁndings, but
that atrial overdrive pacing combined with beta-blockers
should be considered in ATS patients with symptomatic
tachyarrhythmias.Acknowledgments
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